|
1
|
Parr C, Sanders AJ and Jiang WG:
Hepatocyte growth factor activation inhibitors - therapeutic
potential in cancer. Anticancer Agents Med Chem. 10:47–57. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Shimomura T, Denda K, Kitamura A, et al:
Hepatocyte growth factor activator inhibitor, a novel Kunitz-type
serine protease inhibitor. J Biol Chem. 272:6370–6376. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lin CY, Anders J, Johnson M and Dickson
RB: Purification and characterization of a complex containing
matriptase and a Kunitz-type serine protease inhibitor from human
milk. J Biol Chem. 274:18237–18242. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kirchhofer D, Peek M, Lipari MT, et al:
Hepsin activates pro-hepatocyte growth factor and is inhibited by
hepatocyte growth factor activator inhibitor-1B (HAI-1B) and HAI-2.
FEBS Lett. 579:1945–1950. 2005. View Article : Google Scholar
|
|
5
|
Hashimoto T, Kato M, Shimomura T and
Kitamura N: TMPRSS13, a type II transmembrane serine protease, is
inhibited by hepatocyte growth factor activator inhibitor type 1
and activates pro-hepatocyte growth factor. FEBS J. 277:4888–4900.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kato M, Hashimoto T, Shimomura T, et al:
Hepatocyte growth factor activator inhibitor type 1 inhibits
protease activity and proteolytic activation of human airway
trypsin-like protease. J Biochem. 151:179–187. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yao HP, Zhou YQ, Zhang R and Wang MH:
MSP-RON signalling in cancer: pathogenesis and therapeutic
potential. Nat Rev Cancer. 13:466–481. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Eigenbrot C, Ganesan R and Kirchhofer D:
Hepatocyte growth factor activator (HGFA): molecular structure and
interactions with HGFA inhibitor-1 (HAI-1). FEBS J. 277:2215–2222.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bugge TH, Antalis TM and Wu Q: Type II
transmembrane serine proteases. J Biol Chem. 284:23177–23181. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kataoka H, Miyata S, Uchinokura S and Itoh
H: Roles of hepatocyte growth factor (HGF) activator and HGF
activator inhibitor in the pericellular activation of HGF/scatter
factor. Cancer Metastasis Rev. 22:223–236. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shimomura T, Denda K, Kawaguchi T, et al:
Multiple sites of proteolytic cleavage to release soluble forms of
hepatocyte growth factor activator inhibitor type 1 from a
transmembrane form. J Biochem. 126:821–828. 1999. View Article : Google Scholar
|
|
12
|
Kojima K, Tsuzuki S, Fushiki T and Inouye
K: Roles of functional and structural domains of hepatocyte growth
factor activator inhibitor type 1 in the inhibition of matriptase.
J Biol Chem. 283:2478–2487. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Denda K, Shimomura T, Kawaguchi T,
Miyazawa K and Kitamura N: Functional characterization of Kunitz
domains in hepatocyte growth factor activator inhibitor type 1. J
Biol Chem. 277:14053–14059. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kirchhofer D, Peek M, Li W, et al: Tissue
expression, protease specificity, and Kunitz domain functions of
hepatocyte growth factor activator inhibitor-1B (HAI-1B), a new
splice variant of HAI-1. J Biol Chem. 278:36341–36349. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Miyata S, Fukushima T, Kohama K, et al:
Roles of Kunitz domains in the anti-invasive effect of hepatocyte
growth factor activator inhibitor type 1 in human glioblastoma
cells. Hum Cell. 20:100–106. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shia S, Stamos J, Kirchhofer D, et al:
Conformational lability in serine protease active sites: structures
of hepatocyte growth factor activator (HGFA) alone and with the
inhibitory domain from HGFA inhibitor-1B. J Mol Bio. 346:1335–1349.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fan B, Wu TD, Li W and Kirchhofer D:
Identification of hepatocyte growth factor activator inhibitor-1B
as a potential physiological inhibitor of prostasin. J Biol Chem.
280:34513–34520. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Parr C, Watkins G, Mansel RE and Jiang WG:
The hepatocyte growth factor regulatory factors in human breast
cancer. Clin Cancer Res. 10:202–211. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kataoka H, Hamasuna R, Itoh H, Kitamura N
and Koono M: Activation of hepatocyte growth factor/scatter factor
in colorectal carcinoma. Cancer Res. 60:6148–6159. 2000.PubMed/NCBI
|
|
20
|
Yamauchi M, Kataoka H, Itoh H, et al:
Hepatocyte growth factor activator inhibitor types 1 and 2 are
expressed by tubular epithelium in kidney and down-regulated in
renal cell carcinoma. J Urol. 171:890–896. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Dhanasekaran SM, Barrette TR, Ghosh D, et
al: Delineation of prognostic biomarkers in prostate cancer.
Nature. 412:822–826. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wu QY and Parry G: Hepsin and prostate
cancer. Front Biosci. 12:5052–5059. 2007. View Article : Google Scholar
|
|
23
|
Klezovitch O, Chevillet J, Mirosevich J,
et al: Hepsin promotes prostate cancer progression and metastasis.
Cancer Cell. 6:185–195. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Mok SC, Chao J, Skates S, et al:
Prostasin, a potential serum marker for ovarian cancer:
identification through microarray technology. J Natl Cancer Inst.
93:1458–1464. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Takahashi S, Suzuki S, Inaguma S, et al:
Down-regulated expression of prostasin in high-grade or
hormone-refractory human prostate cancers. Prostate. 54:187–193.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Parr C and Jiang WG: Expression of
hepatocyte growth factor/scatter factor, its activator, inhibitors
and the c-Met receptor in human cancer cells. Int J Oncol.
19:857–863. 2001.PubMed/NCBI
|
|
27
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: the next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Nakamura K, Abarzua F, Hongo A, et al: The
role of hepatocyte growth factor activator inhibitor-1 (HAI-1) as a
prognostic indicator in cervical cancer. Int J Oncol. 35:239–248.
2009.PubMed/NCBI
|
|
29
|
Nakamura K, Abarzua F, Hongo A, et al:
Hepatocyte growth factor activator inhibitors (HAI-1 and HAI-2) are
potential targets in uterine leiomyosarcoma. Int J Oncol.
37:605–614. 2010. View Article : Google Scholar
|
|
30
|
Nakamura K, Hongo A, Kodama J and
Hiramatsu Y: The role of hepatocyte growth factor activator
inhibitor (HAI)-1 and HAI-2 in endometrial cancer. Int J Cancer.
128:2613–2624. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Parr C and Jiang WG: Hepatocyte growth
factor activation inhibitors (HAI-1 and HAI-2) regulate HGF-induced
invasion of human breast cancer cells. Int J Cancer. 119:1176–1183.
2006. View Article : Google Scholar
|
|
32
|
Sanders AJ, Parr C, Mason MD and Jiang WG:
Suppression of hepatocyte growth factor activator inhibitor-1 leads
to a more aggressive phenotype of prostate cancer cells in
vitro. Int J Mol Med. 20:613–619. 2007.PubMed/NCBI
|
|
33
|
Baba T, Kawaguchi M, Fukushima T, et al:
Loss of membrane-bound serine protease inhibitor HAI-1 induces oral
squamous cell carcinoma cells’ invasiveness. J Pathol. 228:181–192.
2012.PubMed/NCBI
|
|
34
|
Cheng H, Fukushima T, Takahashi N, Tanaka
H and Kataoka H: Hepatocyte growth factor activator inhibitor type
1 regulates epithelial to mesenchymal transition through
membrane-bound serine proteinases. Cancer Res. 69:1828–1835. 2009.
View Article : Google Scholar
|
|
35
|
Fukushima T, Kawaguchi M, Yamasaki M, et
al: Hepatocyte growth factor activator inhibitor type 1 suppresses
metastatic pulmonary colonization of pancreatic carcinoma cells.
Cancer Sci. 102:407–413. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ye J, Kawaguchi M, Haruyama Y, et al: Loss
of hepatocyte growth factor activator inhibitor type 1 participates
in metastatic spreading of human pancreatic cancer cells in a mouse
orthotopic transplantation model. Cancer Sci. 105:44–51. 2014.
View Article : Google Scholar
|
|
37
|
Nagata K, Hirono S, Ido A, et al:
Expression of hepatocyte growth factor activator and hepatocyte
growth factor activator inhibitor type 1 in human hepatocellular
carcinoma. Biochem Biophys Res Commun. 289:205–211. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zeng L, Cao J and Zhang X: Expression of
serine protease SNC19/matriptase and its inhibitor hepatocyte
growth factor activator inhibitor type 1 in normal and malignant
tissues of gastrointestinal tract. World J Gastroenterol.
11:6202–6207. 2005.PubMed/NCBI
|
|
39
|
Oberst MD, Johnson MD, Dickson RB, et al:
Expression of the serine protease matriptase and its inhibitor
HAI-1 in epithelial ovarian cancer: correlation with clinical
outcome and tumor clinicopathological parameters. Clin Cancer Res.
8:1101–1107. 2002.
|
|
40
|
Saleem M, Adhami VM, Zhong W, et al: A
novel biomarker for staging human prostate adenocarcinoma:
overexpression of matriptase with concomitant loss of its
inhibitor, hepatocyte growth factor activator inhibitor-1. Cancer
Epidemiol Biomarkers Prev. 15:217–227. 2006. View Article : Google Scholar
|
|
41
|
Funagayama M, Kondo K, Chijiiwa K and
Kataoka H: Expression of hepatocyte growth factor activator
inhibitor type 1 in human hepatocellular carcinoma and
postoperative outcomes. World J Surg. 34:1563–1571. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Kataoka H, Suganuma T, Shimomura T, et al:
Distribution of hepatocyte growth factor activator inhibitor type 1
(HAI-1) in human tissues. Cellular surface localization of HAI-1 in
simple columnar epithelium and its modulated expression in injured
and regenerative tissues. J Histochem Cytochem. 47:673–682. 1999.
View Article : Google Scholar
|
|
43
|
Kang JY, Dolled-Filhart M, Ocal IT, et al:
Tissue microarray analysis of hepatocyte growth factor/Met pathway
components reveals a role for Met, matriptase, and hepatocyte
growth factor activator inhibitor 1 in the progression of
node-negative breast cancer. Cancer Res. 63:1101–1105. 2003.
|
|
44
|
Nagaike K, Kohama K, Uchiyama S, et al:
Paradoxically enhanced immunoreactivity of hepatocyte growth factor
activator inhibitor type 1 (HAI-1) in cancer cells at the invasion
front. Cancer Sci. 95:728–735. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Warren M, Twohig M, Pier T, et al: Protein
expression of matriptase and its cognate inhibitor HAI-1 in human
prostate cancer: a tissue microarray and automated quantitative
analysis. Appl Immunohistochem Mol Morphol. 17:23–30. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Yasuda K, Komiya A, Watanabe A, et al:
Expression of Hepatocyte growth factor activator inhibitor type-1
(HAI-1) in prostate cancer. Anticancer Res. 33:575–581.
2013.PubMed/NCBI
|
|
47
|
Nagakawa O, Yamagishi T, Akashi T, Nagaike
K and Fuse H: Serum hepatocyte growth factor activator inhibitor
type I (HAI-I) and type 2 (HAI-2) in prostate cancer. Prostate.
66:447–452. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Hudson BD, Kulp KS and Loots GG: Prostate
cancer invasion and metastasis: insights from mining genomic data.
Brief Funct Genomics. 12:397–410. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Vogel LK, Saebø M, Skjelbred CF, et al:
The ratio of Matriptase/HAI-l mRNA is higher in colorectal cancer
adenomas and carcinomas than corresponding tissue from control
individuals. BMC Cancer. 6:1762006. View Article : Google Scholar
|
|
50
|
Tsai WC, Sheu LF, Chao YC, et al:
Decreased Matriptase/HAI-1 ratio in advanced colorectal
adenocarcinoma of Chinese patients. Chin J Physiol. 50:225–231.
2007.PubMed/NCBI
|
|
51
|
Naldini L, Weidner KM, Vigna E, et al:
Scatter factor and hepatocyte growth factor are indistinguishable
ligands for the MET receptor. EMBO J. 10:2867–2878. 1991.PubMed/NCBI
|
|
52
|
Graveel C, Su Y, Koeman J, et al:
Activating Met mutations produce unique tumor profiles in mice with
selective duplication of the mutant allele. Proc Natl Acad Sci USA.
101:17198–17203. 2004. View Article : Google Scholar
|
|
53
|
Ponzo MG, Lesurf R, Petkiewicz S, et al:
Met induces mammary tumors with diverse histologies and is
associated with poor outcome and human basal breast cancer. Proc
Natl Acad Sci USA. 106:12903–12908. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Rong S, Segal S, Anver M, Resau JH and
Vande Woude GF: Invasiveness and metastasis of NIH 3T3 cells
induced by Met-hepatocyte growth factor/scatter factor autocrine
stimulation. Proc Natl Acad Sci USA. 91:4731–4735. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Meiners S, Brinkmann V, Naundorf H and
Birchmeier W: Role of morphogenetic factors in metastasis of
mammary carcinoma cells. Oncogene. 16:9–20. 1998. View Article : Google Scholar
|
|
56
|
Gallego MI, Bierie B and Hennighausen L:
Targeted expression of HGF/SF in mouse mammary epithelium leads to
metastatic adenosquamous carcinomas through the activation of
multiple signal transduction pathways. Oncogene. 22:8498–8508.
2003. View Article : Google Scholar
|
|
57
|
Jeffers M, Fiscella M, Webb CP, et al: The
mutationally activated Met receptor mediates motility and
metastasis. Proc Natl Acad Sci USA. 95:14417–14422. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Moshitch-Moshkovitz S, Tsarfaty G, Kaufman
DW, et al: In vivo direct molecular imaging of early
tumorigenesis and malignant progression induced by transgenic
expression of GFP-Met. Neoplasia. 8:353–363. 2006. View Article : Google Scholar
|
|
59
|
Abounader R and Laterra J: Scatter
factor/hepatocyte growth factor in brain tumor growth and
angiogenesis. Neuro Oncol. 7:436–451. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Bussolino F, Di Renzo MF, Ziche M, et al:
Hepatocyte growth factor is a potent angiogenic factor which
stimulates endothelial cell motility and growth. J Cell Biol.
119:629–641. 1992. View Article : Google Scholar
|
|
61
|
Grant DS, Kleinman HK, Goldberg ID, et al:
Scatter factor induces blood vessel formation in vivo. Proc
Natl Acad Sci USA. 90:1937–1941. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Santarpia L, Lippman SM and El-Naggar AK:
Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy.
Expert Opin Ther Targets. 16:103–119. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Sami A and Karsy M: Targeting the
PI3K/AKT/mTOR signaling pathway in glioblastoma: novel therapeutic
agents and advances in understanding. Tumour Biol. 34:1991–2002.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Gherardi E, Birchmeier W, Birchmeier C and
Vande Woude G: Targeting MET in cancer: rationale and progress. Nat
Rev Cancer. 12:89–103. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Boettner B and Van Aelst L: Control of
cell adhesion dynamics by Rap1 signaling. Curr Opin Cell Biol.
21:684–693. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Thiery JP: Epithelial-mesenchymal
transitions in tumour progression. Nat Rev Cancer. 2:442–454. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Berx G, Raspé E, Christofori G, Thiery JP
and Sleeman JP: Pre-EMTing metastasis? Recapitulation of
morphogenetic processes in cancer. Clin Exp Metastasis. 24:587–597.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Herter S, Piper DE, Aaron W, et al:
Hepatocyte growth factor is a preferred in vitro substrate
for human hepsin, a membrane-anchored serine protease implicated in
prostate and ovarian cancers. Biochem J. 390:125–136.
2005.PubMed/NCBI
|
|
69
|
Lee SL, Dickson RB and Lin CY: Activation
of hepatocyte growth factor and urokinase/plasminogen activator by
matriptase, an epithelial membrane serine protease. J Biol Chem.
275:36720–36725. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Takeuchi T, Harris JL, Huang W, et al:
Cellular localization of membrane-type serine protease 1 and
identification of protease-activated receptor-2 and single-chain
urokinase-type plasminogen activator as substrates. J Biol Chem.
275:26333–26342. 2000. View Article : Google Scholar
|
|
71
|
Liotta LA: Tumor invasion and metastases -
role of the extracellular matrix: Rhoads Memorial Award lecture.
Cancer Res. 46:1–7. 1986.PubMed/NCBI
|
|
72
|
Hoshiko S, Kawaguchi M, Fukushima T, et
al: Hepatocyte growth factor activator inhibitor type 1 is a
suppressor of intestinal tumorigenesis. Cancer Res. 73:2659–2670.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Turner JR: Intestinal mucosal barrier
function in health and disease. Nat Rev Immunol. 9:799–809. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Turksen K and Troy TC: Junctions gone bad:
Claudins and loss of the barrier in cancer. Biochim Biophys Acta.
1816:73–79. 2011.PubMed/NCBI
|
|
75
|
Kataoka H, Shimomura T, Kawaguchi T, et
al: Hepatocyte growth factor activator inhibitor type 1 is a
specific cell surface binding protein of hepatocyte growth factor
activator (HGFA) and regulates HGFA activity in the pericellular
microenvironment. J Biol Chem. 275:40453–40462. 2000. View Article : Google Scholar
|
|
76
|
Oberst MD, Williams CA, Dickson RB,
Johnson MD and Lin CY: The activation of matriptase requires its
noncatalytic domains, serine protease domain, and its cognate
inhibitor. J Biol Chem. 278:26773–26779. 2003. View Article : Google Scholar
|
